<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 4 月 22 日至 2026 年 2 月 9 日期间（包括该日期，以下简称 “集体诉讼期间”）购买 Medpace Holdings, Inc.（纳斯达克代码：MEDP）普通股的投资者，注意 2026 年 6 月 8 日的重要首席原告截止日期。</p>
<p>那么：如果您在集体诉讼期间购买了 Medpace 普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 Medpace 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=58453 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 6 月 8 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。这些律师事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行案件诉讼的律师事务所合作。选择律师时要谨慎。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并/或隐瞒了关于 Medpace 的积压取消率真实状态的重大不利事实。实际上，被告不断宣称取消率 “表现良好”。此外，Medpace 明确表示，取消并不是由于业务疲软或融资环境疲软，给投资者提供了过于乐观的增长预期，无法维持预期的 1.15 账单比率。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 Medpace 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=58453 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所，P.A.</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>New York, NY 10016</p>
<p>电话：(212) 686-1060</p>
<p>免费电话：(866) 767-3653</p>
<p>传真：(212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所，P.A.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9REM1ODMyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMwMjI3UFJfTkVXU19VU1BSX19fX19EQzU4MzI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9REM1ODMyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMwMjI3UFJfTkVXU19VU1BSX19fX19EQzU4MzI0"/></p>

Medpace控股

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>罗斯律师事务所提醒在 2025 年 4 月 22 日至 2026 年 2 月 9 日期间购买了 Medpace Holdings, Inc.（纳斯达克代码：MEDP）普通股的投资者，注意 2026 年 6 月 8 日提起证券欺诈诉讼的截止日期。该事务所声称，Medpace 误导了投资者关于其订单取消率的信息，导致真相浮出水面时造成损失。投资者可以在没有前期费用的情况下加入集体诉讼。如需更多信息，请联系 Phillip Kim 律师，电话：866-767-3653 或通过电子邮件联系</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Medpace Holdings, Inc. (NASDAQ: MEDP) between April 22, 2025 and February 9, 2026, inclusive (the &#34;Class Period&#34;), of the important June 8, 2026 lead plaintiff deadline.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 4 月 22 日至 2026 年 2 月 9 日期间（包括该日期，以下简称 “集体诉讼期间”）购买 Medpace Holdings, Inc.（纳斯达克代码：MEDP）普通股的投资者，注意 2026 年 6 月 8 日的重要首席原告截止日期。</p>
</div><p>So what: If you purchased Medpace common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您在集体诉讼期间购买了 Medpace 普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 8, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 Medpace 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=58453 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已被提起。如果您希望担任首席原告，必须在 2026 年 6 月 8 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases <strong>.</strong> Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。这些律师事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行案件诉讼的律师事务所合作。选择律师时要谨慎。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者争取了超过 4.38 亿美元。2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of Medpace's backlog cancellation rate. In fact, defendants continuously touted &#34;well behaved&#34; cancellation rates. Furthermore, Medpace made clear that cancellations were not caused by weak business or a weak funding environment, providing investors with overly positive growth expectations that could not maintain the projected 1.15 book-to-bill ratio. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件详情：根据诉讼，整个集体诉讼期间，被告做出了虚假和/或误导性的陈述，并/或隐瞒了关于 Medpace 的积压取消率真实状态的重大不利事实。实际上，被告不断宣称取消率 “表现良好”。此外，Medpace 明确表示，取消并不是由于业务疲软或融资环境疲软，给投资者提供了过于乐观的增长预期，无法维持预期的 1.15 账单比率。当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the Medpace class action, go to https://rosenlegal.com/submit-form/?case_id=58453 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Medpace 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=58453 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证，您不会被律师代表，除非您聘请一位。您可以选择自己选择的律师。您也可以保持缺席集体成员身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>请关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所，P.A.</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>New York, NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：(212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：(866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：(212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所，P.A.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTEzJk5ld3NJdGVtSWQ9REM1ODMyNCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTMwMjI3UFJfTkVXU19VU1BSX19fX19EQzU4MzI0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC58324&amp;Transmission_Id=202605130227PR_NEWS_USPR_____DC58324&amp;DateId=20260513"/></p>

02:27 ETMEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit

prnewswire

医疗业 ETF - SPDR

标普生物技术 3 倍做空 - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

美国医疗保健供应商 ETF - iShares

标普生物技术 3 倍做多 - Direxion

美国医药设备 ETF - iShares

基因免疫&健康关怀 ETF - iShares

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

标普健康医疗设备 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

02:27 ETMEDP 投资者有机会主导对 Medpace 控股公司的证券欺诈诉讼